Follow The Filings

CATX Perspective Therapeutics Inc.

Health Care, filed as PERSPECTIVE THERAPEUTICS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 3.4%
  • $21M
  • 1 exit 1 small

In 2026 Q2 James Silverman sold out of Perspective Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 3.4% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke Add 3.4%

Who owns CATX

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 3.4% Small add +4.1% 6,299,999 $21M History
James Silverman, Opaleye Management exited 2026 Q2 Last 2026 Q1 2.6% Exit −2.57% 4,675,000 $19M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CATX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CATX insider trades
  • $42K bought by 2 insiders
  • $1.6M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Lantheus Alpha Therapy, LLC 10% owner, +1 joint filer
    Sale
    $777K 247,932 shares at $3.13 2.2% of stake
    Traded Sep 3–4 Filed Sep 8
  2. Lantheus Alpha Therapy, LLC 10% owner, +1 joint filer
    Sale
    $131K 42,129 shares at $3.11 0.4% of stake
    Traded Sep 2 Filed Sep 4
  3. Lantheus Alpha Therapy, LLC 10% owner
    Sale
    $357K 113,914 shares at $3.14 1% of stake
    Traded Aug 31–Sep 1 Filed Sep 4
  4. Lantheus Holdings, Inc. 10% owner
    Sale
    $112K 35,769 shares at $3.12 0.3% of stake
    Traded Sep 1 Filed Sep 3
  5. Lantheus Holdings, Inc. 10% owner
    Sale
    $246K 78,145 shares at $3.14 0.7% of stake
    Traded Aug 31 Filed Sep 2
  6. Jonathan Robert Hunt Chief Accounting Officer
    Buy
    $22K 11,000 shares at $2.03 +23% to stake
    Traded Nov 13, 2025 Filed Nov 17, 2025
  7. Robert F Williamson III Director
    Buy
    $20K 9,498 shares at $2.10 +2595% to stake
    Traded Nov 12, 2025 Filed Nov 14, 2025

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
SCHEDULE 13D/A —
8-K 8.01,9.01
8-K 8.01,9.01
SCHEDULE 13D/A —
SCHEDULE 13G/A —
8-K 2.02,8.01,9.01
10-Q
SCHEDULE 13G —
8-K 8.01,9.01
SCHEDULE 13G —
SCHEDULE 13G —
8-K 8.01,9.01
SCHEDULE 13G —
8-K 8.01,9.01
8-K 5.07
8-K 8.01,9.01
SCHEDULE 13G/A —
8-K 2.02,8.01,9.01
10-Q
8-K 2.02,8.01,9.01
SCHEDULE 13G/A —
8-K 8.01,9.01

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.43M — —
Gross profit $1.43M — —
Gross margin * 100.0% — —
Net income -$46.51M -$79.28M -$103.12M
Net margin * -3243.2% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $16.84M $231.16M $148.39M
Total non-current assets * $81.05M $109.94M $118.58M
Total assets $97.89M $341.1M $266.97M
Total current liabilities $15.66M $18.23M $28.68M
Total non-current liabilities * $7.05M $32.2M $31.26M
Total equity $75.18M $290.67M $207.03M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$36.91M -$18.29M -$82.48M
Cash from investing $24.37M -$218.93M $41.23M
Cash from financing $0.785M $289.38M $10.3M
Net change in cash -$11.76M $52.16M -$30.95M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.